Skip to main content
SpringerLink
Log in

S3-Leitlinie „Interdisziplinäre Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms“

Aktuelle Neuerungen der S3-Leitlinie „Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms“ (AWMF-Registernummer: 032-045 OL)

German S3 guideline “Interdisciplinary screening, diagnosis, treatment, and follow-up of breast cancer”

Latest improvements to the S3 guideline “Screening, diagnosis, treatment, and follow-up of breast cancer” (AWMF register number: 032-045 OL)

  • Onkologische Leitlinie - kurzgefasst
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Caumo F et al (2014) Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection evident for screening centres in a population-based trial. Breast 23(1):76–80

    Article  Google Scholar 

  2. Lang K et al (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmo Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol 26(1):184–190

    Article  Google Scholar 

  3. Skaane P et al (2014) Two-view digital breast tomosynthesis screening with synthetically reconstructed projection images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 271(3):655–663

    Article  Google Scholar 

  4. Hahnen E et al (2017) Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol 3(10):1378–1385

    Article  Google Scholar 

  5. Liu M et al (2013) Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis. Oncol Lett 5(3):983–991

    Article  CAS  Google Scholar 

  6. Moran MS et al (2014) Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32(14):1507–1515

    Article  Google Scholar 

  7. Lyman GH, Somerfield MR, Giuliano AE (2017) Sentinel lymph node biopsy for patients with early-stage breast cancer: 2016 American Society of Clinical Oncology clinical practice guideline update summary. J Oncol Pract 13(3):196–198

    Article  Google Scholar 

  8. McCormick B et al (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709–715

    Article  CAS  Google Scholar 

  9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Article  Google Scholar 

  10. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747

    Article  CAS  Google Scholar 

  11. Department of Health (2015) National Clinical Guideline—Diagnosis, staging and treatment of patients with breast cancer. National Clinical Guideline No. 7

    Google Scholar 

  12. Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784

    Article  CAS  Google Scholar 

  13. Eisen A, Fletcher GG, Gandhi S et al (2014) Optimal systemic therapy for early female breast Cancer. Evidence-based series, S 1–21

    Google Scholar 

  14. Aebi S et al (2014) Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 15(2):156–163

    Article  CAS  Google Scholar 

  15. Finn RS et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35

    Article  CAS  Google Scholar 

  16. Hortobagyi GN et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748

    Article  CAS  Google Scholar 

  17. Runowicz CD et al (2016) American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34(6):611–635

    Article  CAS  Google Scholar 

  18. Wöckel A et al (2018) Früherkennung, Diagnostik, Therapie und Nachsorge des primären Mammakarzinoms. Dtsch Arztebl Int 115(18):316–323. https://doi.org/10.3238/arztebl.2018.0316

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wöckel A, Stüber T (2018) Gynäkologe 51:807. https://doi.org/10.1007/s00129-018-4316-39

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frauenklinik und Poliklinik, Universitätsklinikum Würzburg, Josef-Schneider-Straße 4, 97080, Würzburg, Deutschland

    Achim Wöckel & Tanja Stüber

Authors
  1. Achim Wöckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanja Stüber
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

die gesamte Leitlinienkommission

Corresponding author

Correspondence to Achim Wöckel.

Ethics declarations

Interessenkonflikt

A. Wöckel erhielt Honorare für Vorträge und Beratungen von Novartis, Pfizer, Celgene, Aurikamed, Tesaro, Lilly, Amgen. T. Stüber gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Teile dieses Beitrags finden sich in der Langversion der Leitlinie, einem Beitrag in Deutsches Ärzteblatt [18] und der DGGG-Kongressausgabe Der Gynäkologe 2018 [19]. Die gesamte Leitlinie inkl. der Liste aller Mitglieder der Steuerungsgruppe, der beteiligten Fachgesellschaften und Organisationen sowie der Experten in beratender Funktion findet sich als Lang- und Kurzfassung unter https://www.leitlinienprogramm-onkologie.de.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wöckel, A., Stüber, T. & die gesamte Leitlinienkommission. S3-Leitlinie „Interdisziplinäre Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms“. Forum 34, 139–143 (2019). https://doi.org/10.1007/s12312-019-0561-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-019-0561-1

Search

Navigation